All Stories

  1. Post-mortem human brain evidence for presynaptic dopaminergic dysregulation in cocaine use disorder: A systematic review
  2. Emerging pharmacological and neuromodulation interventions for suicidal ideation and behaviour
  3. The multivariate genetic architecture of psychiatric and insulin resistance multimorbidity
  4. Potential for Genomics to Help Guide Preventive Strategies in Psychiatry
  5. Damped Physical Activity and Unstable Sleep: Fitbit-Derived Rest-Activity Phenotypes in Inter-episode Mood Disorders
  6. Transdiagnostic Domain-specific Cognitive Impairment in Inter-episode Mood Disorders and its Relationship with Rest-Activity Phenotypes
  7. Shared genetic and molecular architecture between insulin resistance and cognitive performance
  8. Educational Attainment Polygenic Scores and School Performance in Adolescents With Psychiatric Disorders: A Population-Based Analysis of 86,122 Individuals From the iPSYCH2015 Case-Cohort
  9. Dissecting the pleiotropic genetic architecture of suicide attempt, suicidal ideation, and thirteen correlated traits
  10. Suicidality phenotypes reflect both shared and distinct genetic factors
  11. Risk of all‐cause and cause‐specific mortality, and suicide attempt in people with anxiety and stress‐related disorders: a systematic review, meta‐analysis and meta‐regression analysis of 165 studies
  12. Drug development in autism spectrum disorder: genetic heterogeneity, failed trials, and the case for stratified pharmacotherapy
  13. Sociability and whole-brain resting-state connectivity
  14. Magnetoencephalographic Signatures of Facial Emotion Processing in Schizophrenia and Major Depressive Disorder: A Systematic Review
  15. Shared genetic architecture between psychiatric and insulin-related traits in the general population
  16. Associations between transdiagnostic polygenic liability and antidepressant outcomes in major depressive disorder
  17. Dissecting the pleiotropic genetic architecture of suicide attempt, suicidal ideation, and correlated psychiatric and non-psychiatric traits
  18. Emotion recognition using human avatars in schizophrenia: sex differences between non- immersive and immersive virtual reality
  19. Facial emotion recognition with virtual avatars in schizophrenia and bipolar disorder
  20. Polygenic predisposition to transdiagnostic symptom dimensions and treatment outcomes across psychiatric disorders
  21. Predictors of remission and treatment outcomes in first episode psychosis: insights from the 2-year parma early psychosis programme
  22. Psychiatric-insulin resistance multimorbidity: exploring the joint transcriptomic background
  23. The common genetic and molecular background of insulin resistance and cognitive functions
  24. The genetic link between cognitive domains and insulin resistance
  25. Dissecting the pleiotropic genetic architecture of suicide attempt, suicidal ideation, and thirteen correlated traits
  26. The association of glycemic dysregulation with cognitive decline and structural MRI brain volumes in The Maastricht Study – A role for peripheral inflammation?
  27. Personality domains in early stages of psychosis: a systematic review and meta-analysis
  28. Genome-wide association studies identify 77 loci for suicidality and provide novel biological insights
  29. Polygenic liability to C-reactive protein defines immunometabolic depression phenotypes and influences antidepressant therapeutic outcomes
  30. Schizophrenia Genetics Modulates Clinical Depressive Features
  31. Polygenic predisposition to transdiagnostic symptom dimensions and treatment outcomes across psychiatric disorders
  32. The association of diabetes with Alzheimer's disease biomarkers and vascular burden across European aging and memory clinic cohorts
  33. Psychiatric Risk Governance Across Jurisdictions: A Comparative Analysis of Involuntary Treatment, Community Treatment Orders, and Forensic Mental Health Services
  34. Asenapine for aggressive behaviours in psychiatric disorders: a systematic review of efficacy and real-world effectiveness
  35. Factors associated with drug–drug interactions involving citalopram in the UK Biobank
  36. Predicted plasma proteomics from genetic scores and treatment outcomes in major depression: a meta-analysis
  37. Insulin resistance and poorer treatment outcomes in depression: evidence from UK Biobank primary care data
  38. Correction: Mild motor signs and depression: more than just medication side effects?
  39. Mild motor signs and depression: more than just medication side effects?
  40. Local patterns of genetic sharing between neuropsychiatric and insulin resistance-related conditions
  41. Specific symptomatology profile associated with treatment resistant depression: A multicentric study from the Group for the Study of Resistant Depression with a focus on sex
  42. Oropharyngeal microbiota in patients with psychotic disorders: A scoping review on compositional and functional alterations
  43. Predictive coding in neuropsychiatric disorders: A systematic transdiagnostic review
  44. COGNITIVE FUNCTIONS AND PERSONALITY DOMAINS IN PATIENTS WITH FIRST-EPISODE PSYCHOSIS
  45. PERSONALITY DOMAINS AND NEGATIVE SYMPTOMS IN FIRST-EPISODE PSYCHOSIS
  46. The interface of depression and diabetes: treatment considerations
  47. Shared genetics and causal relationship between sociability and the brain’s default mode network
  48. Polygenic scores and antidepressant treatment outcomes in major depression: a critical integrative review
  49. The gut microbiota's role in bulimia nervosa and binge eating disorder: etiological insights and therapeutic implications from a scoping review
  50. Differences in emotion recognition between nonimmersive versus immersive virtual reality: preliminary findings in schizophrenia and bipolar disorder
  51. The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges
  52. Anhedonia is associated with a specific depression profile and poor antidepressant response
  53. Molecular landscape of the overlap between Alzheimer’s disease and somatic insulin-related diseases
  54. Unravelling the joint genetic architecture between psychiatic and insulin-related traits in the general population
  55. The multivariate genetic architecture of psychiatric and insulin resistance multimorbidity
  56. F59. DISENTANGLING THE OVERLAP BETWEEN SUICIDE ATTEMPT AND ASSOCIATED PHENOTYPES USING LOCAL GENETIC CORRELATIONS
  57. W99. TRANSCRIPTOME-WIDE STRUCTURAL EQUATION MODELLING OF PSYCHIATRIC-INSULIN RESISTANCE MULTIMORBIDITY
  58. Genetic factors and symptom dimensions associated with antidepressant treatment outcomes: clues for new potential therapeutic targets?
  59. The clinical perspective on late-onset depression in European real-world treatment settings
  60. Mirtazapine blood levels and antidepressant response
  61. Shared familial risk for type 2 diabetes mellitus and psychiatric disorders: a nationwide multigenerational genetics study
  62. Shared genetics linking sociability with the brain's default mode network.
  63. The association of glucose metabolism measures and diabetes status with Alzheimer’s disease biomarkers of amyloid and tau: A systematic review and meta-analysis
  64. Local patterns of genetic sharing challenge the boundaries between neuropsychiatric and insulin resistance-related conditions
  65. Pharmacological treatments for psychotic depression: a systematic review and network meta-analysis
  66. The bidirectional interaction between antidepressants and the gut microbiota: are there implications for treatment response?
  67. Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression
  68. Cognitive functioning in patients with first-episode of psychosis screened for ADHD: an exploratory study
  69. Gene-level cross-disorder analysis of metabolic and mental disorder pairs
  70. Genetic factors and symptom dimensions associated with antidepressant treatment outcomes: clues for new potential therapeutic targets?
  71. Insights into trauma and narcissistic traits: a case report
  72. Looking beyond labels: genetics of psychiatric traits cluster with insulin-related measures
  73. Mental state decoding, cognitive functions, and psychopathology in patients with first-episode of schizophrenia
  74. Predicted plasma proteomics and antidepressant response in major depressive disorder: a meta-analysis
  75. Unravelling the genetic architecture underlying the multimorbidity between psychiatric disorders and somatic insulin resistance-related conditions
  76. Genetic relationship between the immune system and autism
  77. Genetic relationship between the immune system and autism spectrum disorder and traits
  78. 33. SHARED GENETICS LINKING SOCIABILITY WITH THE BRAIN'S DEFAULT MODE NETWORK
  79. T13. EPIGENETIC FACTORS INFLUENCING CO-MORBIDITY OF INSULIN-RELATED SOMATIC AND BRAIN DISORDERS
  80. W12. LOOKING BEYOND LABELS: DEFINING DIMENSIONAL PSYCHIATRIC SYMPTOM CLUSTERS WITH INSULIN-RELATED SOMATIC MEASURES BASED ON LARGE POPULATION-BASED GENETIC DATASETS
  81. W16. THE MULTIVARIATE GENETIC ARCHITECTURE OF PSYCHIATRIC AND SOMATIC INSULIN RESISTANCE-RELATED MULTIMORBIDITY
  82. Correlation between emotion dysregulation and mood symptoms of bipolar disorder: A systematic review and meta‐analysis
  83. Clinical insights into the cross-link between mood disorders and type 2 diabetes: A review of longitudinal studies and Mendelian randomisation analyses
  84. Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression
  85. Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database
  86. Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder
  87. Clinical specificity profile for novel rapid acting antidepressant drugs
  88. Age or age of onset: which is the best criterion to classify late-life depression?
  89. Clinical correlates and prognostic implications of severe suicidal ideation in major depressive disorder
  90. Hyperthyroidism and depression: a clinical case of atypical thyrotoxicosis manifestation
  91. Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns
  92. Association between polygenic risk scores of subcortical brain volumes and antidepressant response: a meta-analysis
  93. Emotional side effects of antidepressants: a systematic review
  94. Epigenetic factors influencing the multimorbidity between somatic and brain-insulinopathies
  95. Pharmacological treatment of psychotic depression: a systematic review and network meta-analysis
  96. What emotional regulation strategies are most related to the affective symptoms of bipolar disorder? A systematic review and network meta-analysis
  97. The link between cognition and somatic conditions related to insulin resistance in the UK Biobank study cohort: a systematic review
  98. LOCAL PATTERNS OF SHARED GENETICS AND A GENETIC LATENT FACTOR OF INSULIN RESISTANCE AND NEUROPSYCHIATRIC MULTIMORBIDITY
  99. PSYCHIATRIC AND INSULIN-RELATED SOMATIC MULTIMORBIDITY: INSIGHTS INTO UNDERLYING GENETIC ARCHITECTURE AND BRAIN STRUCTURES INVOLVED
  100. T75. NO LABELS NEEDED: UNDERSTANDING PSYCHIATRIC DISORDERS BASED ON GENETIC TRAITS
  101. Patterns of antipsychotic prescription and accelerometer-based physical activity levels in people with schizophrenia spectrum disorders: a multicenter, prospective study
  102. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders
  103. The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs
  104. Temporally ordered associations between type 2 diabetes and brain disorders – a Danish register-based cohort study
  105. The Italian version of the Brief Assessment of Cognition in Affective Disorders: performance of patients with bipolar disorder and healthy controls
  106. Epigenetics and aetiology of mental illness
  107. Clinical correlates and prognostic impact of binge-eating symptoms in major depressive disorder
  108. The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?
  109. Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder
  110. Depression, antidepressants, and insulin resistance: which link?
  111. The U-shaped relationship between parental age and the risk of bipolar disorder in the offspring: A systematic review and meta-analysis
  112. Epigenetic Basis of Psychiatric Disorders: A Narrative Review
  113. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder
  114. Polygenic risk scores for neuropsychiatric, inflammatory, and cardio‐metabolic traits highlight possible genetic overlap with suicide attempt and treatment‐emergent suicidal ideation
  115. Obsessive-compulsive symptoms in major depressive disorder correlate with clinical severity and mixed features
  116. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders
  117. A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response
  118. The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
  119. Bipolar disorder and comorbid substance use disorder: a machine-learning approach
  120. Genetic dissection of the clinical heterogeneity of major depressive disorder
  121. Hyperthyroidism and depression: a clinical case of atypical thyrotoxicosis manifestation
  122. Hyperthyroidism and depression: focusing on this complex interplay
  123. The Italian Version of the Brief Assessment of Cognition in Affective Disorders: Performance of Patients with Bipolar Disorder and Healthy Controls
  124. The U-shaped relationship between parental age and the risk of bipolar disorder in the offspring – A systematic review and meta-analysis
  125. The cross-link between major depressive disorder and type 2 diabetes mellitus: a review of longitudinal and mendelian randomisation studies
  126. Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts
  127. P.0882 A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response
  128. W68. A META-ANALYSIS OF POLYGENIC RISK SCORES FOR MOOD DISORDERS, NEUROTICISM, AND SCHIZOPHRENIA IN ANTIDEPRESSANT RESPONSE
  129. TH59. INSULINOPATHIES OF THE BRAIN? GENETIC OVERLAP BETWEEN SOMATIC INSULIN-RELATED AND NEUROPSYCHIATRIC DISORDERS
  130. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis
  131. A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response
  132. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder
  133. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders
  134. Polygenic risk scores for psychiatric, inflammatory, and cardio-metabolic traits and diseases highlight possible genetic overlaps with suicide attempt and treatment-emergent suicidal ideation
  135. P.169 Genetic overlap between somatic insulin-related and neuro-psychiatric disorders
  136. P.171 Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder
  137. P.179 Polygenic risk scores for multiple psychiatric, inflammatory and cardio-metabolic traits highlight possible genetic overlap with suicide attempt
  138. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder
  139. Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly
  140. P.306 Reduced chemokine ligand 1/GRO chemokine plasma levels are a possible biomarker of elderly depression
  141. M74 HIGHER POLYGENIC RISK SCORES FOR SCHIZOPHRENIA MAY BE SUGGESTIVE OF NON-RESPONSE TO DRUGS FOR DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
  142. Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression
  143. P.4.01 C-X-C chemokine signalling is implicated in major depressive disorder in a sample of Korean elderly subjects
  144. SA92THE INFLUENCE OF THE SEROTONIN TRANSPORTER GENE 5-HTTLPR POLYMORPHISM ON SUICIDAL BEHAVIORS: A META-ANALYSIS
  145. The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behavior: a meta-analysis
  146. The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behaviors: a meta-analysis
  147. A Polygenic Risk Score of glutamatergic SNPs associated with schizophrenia predicts attentional behavior and related brain activity in healthy humans